{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Defined as the percentage of checkpoint inhibitor-naive melanoma participants who have a CR based on investigator assessment per RECIST v1.1","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"populationDescription":"The study was terminated early and no participants enrolled in Phase 2 of the study.","reportingStatus":"POSTED","timeFrame":"Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months","title":"Phase 2: Complete Response Rate (CRR) Based on RECIST v1.1","type":"PRIMARY"}